[The efficacy of treating glomerulonephritis patients with a hematuria component].
A clinical evaluation was carried out of treatment efficacy of patients suffering of glomerulonephritis with hematuria component.


METHODS
membrane stabilizing therapy including unithiol, dimephosphon (delagil) and alpha-tocopherol acetate. Duration of this treatment was 1 month; 2 months--with alpha-tocopherol and delagil; 6 months--with delagil. TREATMENT was carried out in 80 patients. Six-month follow-up was evaluated in 62 patients. In 48 patients the treatment was effective as concerns proteinuria and in 4--only hematuria. Comparing the results of such treatment with indomethacin treatment where a positive dynamics was observed in 10 of 38 patients and only in 2 patients improvement concerned proteinuria and erythrocyturia.


CONCLUSIONS
membrane stabilizing therapy is the method of choice in comparison with traditional indomethacin treatment.
Pyrih
L A
LA
Dudar
I O
IO
Kolesnyk
M O
MO
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D002738:Chloroquine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005921:Glomerulonephritis / Q000150:complications / Q000188:drug therapy*; D006417:Hematuria / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D009943:Organophosphorus Compounds / Q000627:therapeutic use; D012074:Remission Induction; D014494:Unithiol / Q000627:therapeutic use; D014810:Vitamin E / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000894:Anti-Inflammatory Agents, Non-Steroidal; D009943:Organophosphorus Compounds; C049638:dimephosphon; D014810:Vitamin E; D014494:Unithiol; C023676:chloroquine diphosphate; D002738:Chloroquine
Efekyvnist' likuvannia khvorykh na hlomerulonefryt z hematurychnym komponentom.